Business Context and Reporting Period
This Form 8-K filing by Xencor, Inc. (XNCR) reports corporate governance and executive leadership changes effective May 1, 2023. The report date is April 24, 2023.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on personnel changes and associated compensation arrangements.
Material Changes
- Board Resignation: Dr. Nancy Valente resigned from the Board of Directors, effective May 1, 2023.
- Board Size Reduction: The Board reduced its size from eight to seven directors to eliminate the vacant seat.
- Executive Transition: Dr. Allen Yang stepped down as an executive officer effective May 1, 2023, remaining with the company in a non-executive capacity.
- New Appointment: Dr. Nancy Valente was appointed Executive Vice President and Chief Development Officer, effective May 1, 2023.
Compensation and Management Commentary
Management highlighted Dr. Valente's over 20 years of experience in late-stage drug development, including significant roles at Roche and Genentech. Her compensation package includes:
- Base Salary: $540,000 annually.
- Bonus: Eligibility for an annual discretionary bonus of up to 50% of base salary.
- Stock Options: Grant of 235,778 options valued at $3,937,500, vesting 25% after one year and monthly thereafter.
- RSUs: Grant of 39,269 Restricted Stock Units valued at approximately $1,312,500, vesting annually over three years.
- Severance: In the event of termination without Cause, Dr. Valente is eligible for 12 months of base salary and COBRA premium coverage.
- Change in Control: Accelerated vesting provisions apply if termination occurs in connection with a Change in Control.
Investor Verification Checklist
- Verify the impact of Dr. Yang's departure on ongoing executive operations.
- Review the vesting schedule and dilution impact of the new equity grants (options and RSUs) to Dr. Valente.
- Confirm the strategic rationale for reducing the Board size from eight to seven members.
- Check subsequent filings for any updates to the Board composition or additional executive appointments.